PPAR-γ agonists reduce atherosclerosis in humanpatients and animal models [88–92] even though there wereconcerns that these compounds could be proatherogenic because they may promotethe macrophages uptake of lipids and speed the foam cell formation [26]. The gene discussed is PPARG; the disease is atherosclerosis.